A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

  • STATUS
    Recruiting
  • End date
    Nov 1, 2027
  • participants needed
    12
  • sponsor
    Continuity Biosciences, LLC
Send
Updated on 21 March 2026
See if I qualify

Summary

This study is being done to find out if delivering gemcitabine using the ACT-IOP-003 device directly to the area where the tumor is in the pancreas is safe and tolerable.

The main questions the study aims to answer are:

  • Is ACT-IOP-003 safe and tolerable when given to patients with nonmetastatic, locally advanced, nonresectable pancreatic cancer.
  • How much study drug (gemcitabine) is found in the blood before and after treatment.
  • If the tumor responds to treatment.
  • If the gemcitabine side effects are less than seen when delivered intravenously (IV).

Study participants will:

  • Have the study device surgically placed on the pancreas at the beginning of the study.
  • Complete 8 weeks of treatment with a 4 week screening period and 12 weeks of follow-up for a total of 24 weeks of participation in the study.
  • Give blood, urine, and stool samples to monitor safety and determine how much of the study drug (gemcitabine) is in the blood.
  • Have imaging (CT) done at least three times during the study.

Details
Condition Pancreatic Adenocarcinoma Non-resectable
Age 18years or above
Clinical Study IdentifierNCT07481383
SponsorContinuity Biosciences, LLC
Last Modified on21 March 2026

Eligibility

 Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Diagnosis of nonmetastatic, nonresectable pancreatic adenocarcinoma as evident on initial study. screening computed tomography (CT) or magnetic resonance imaging (MRI) or previous scan within the last 12 weeks
Initial diagnosis of borderline or locally advanced pancreatic adenocarcinoma confirmed as being nonresectable at the time of exploratory laparoscopic and/ or open surgery
Previously received prior standard of care/neoadjuvant chemotherapy of FOLFIRINOX or GEM Abraxane for their current diagnosis of pancreatic cancer

Exclusion Criteria

Current pancreatitis classified as severe or critical
Prior radiation treatment as part of standard of care/neoadjuvant treatment for pancreatic cancer
Evidence of metastatic pancreatic cancer or any other type of cancer upon screening of through CT/MRI
Any medical history of past or present cardiovascular disease related to heart function
Any metal implants
Note: Other inclusion/exclusion criteria apply
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.